TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

Key Points

• TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus rating of "Buy" from five brokerages, with an average 1-year price target of $7.80.
• The company's recent earnings report indicated revenue of $3.08 million for the quarter, significantly exceeding the consensus estimate of $1.31 million.
• TScan Therapeutics is a clinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for cancer, currently conducting Phase I trials for its lead product candidates.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Buy" from the five brokerages that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.80.

A number of research analysts have recently commented on TCRX shares. Wedbush reissued an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, HC Wainwright dropped their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th.

TScan Therapeutics Trading Down 1.1%

Shares of TCRX stock opened at $1.87 on Thursday. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The stock's fifty day moving average price is $1.71 and its two-hundred day moving average price is $1.63. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. The company has a market cap of $106.12 million, a PE ratio of -1.72 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. Equities analysts predict that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC bought a new stake in shares of TScan Therapeutics in the fourth quarter worth $40,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $26,000. Squarepoint Ops LLC bought a new stake in shares of TScan Therapeutics in the 4th quarter valued at about $59,000. Wells Fargo & Company MN increased its stake in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after buying an additional 5,694 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of TScan Therapeutics during the second quarter worth about $29,000. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.